Moderna and Merck’s positive Phase III results for their personalised mRNA cancer therapy have exposed a manufacturing problem – how do you produce a different treatment for every patient, reliably and at scale?

Their investigational therapy, intismeran autogene (formerly V940/mRNA-4157), combined with Keytruda, demonstrated statistically significant improvements in recurrence-free and distant metastasis-free survival versus Keytruda alone in the Phase III INTerpath-001 trial. The findings came from a prespecified interim analysis involving patients with surgically removed melanoma.

Unlike conventional vaccines manufactured in large batches, individualised treatments require patient-specific production and quality control. Making this approach commercially viable will require manufacturers to control costs without compromising treatment timelines.

Visiongain Top Takeaways

• Personalised oncology puts manufacturing under pressure. Clinical progress is raising expectations for patient-specific production, turnaround times and batch release.
• Integrated services are gaining ground. Recent CDMO investments and partnerships highlight different approaches to connecting specialist manufacturing capabilities.
• Supply-chain resilience remains a commercial risk. Critical materials, supplier qualification and trade-policy uncertainty could influence outsourcing decisions.

mRNA Manufacturing: Integration Takes Two Routes

A 28 September 2026 agreement between 4basebio and TriLink BioTechnologies illustrates one approach to coordinating specialist manufacturing capabilities.

4basebio will supply synthetic DNA starting material for a pharmaceutical company’s Phase I cell therapy programme, while TriLink, part of Maravai LifeSciences, will manufacture the mRNA drug substance using its CleanCap technology.

Artis BioSolutions is pursuing a different model. Its Genetic Medicines Center of Excellence in Bilbao, announced on 26 August 2026, brings synthetic DNA, mRNA manufacturing, LNP formulation and GMP drug-product services into an integrated offering.

Both approaches aim to simplify the management of manufacturing programmes. Working with multiple suppliers can mean additional quality agreements, technology transfers and production handovers. Integration may reduce delays and improve accountability, although heavy reliance on a single provider brings its own risks.

Sponsors will need evidence that these arrangements improve delivery and reduce costs. Offering more services does not necessarily mean better manufacturing performance.

Personalised mRNA Therapies Put Manufacturing to the Test

A paper published in JCO Oncology Advances in August 2026, authored by Moderna researchers and colleagues, offers a measure of what individualised production can achieve. Manufacturing succeeded in more than 99% of patients for whom suitable neoantigens had been selected, with treatment reaching clinical sites approximately six weeks after adequate tumour and blood samples were submitted.

The figures demonstrate what is achievable in clinical trials, but reveal little about manufacturing costs at commercial scale.

Conventional vaccines can be produced in larger batches as demand grows. Personalised treatments require more individual batches to run in parallel, increasing the demands on scheduling, quality testing and release.

Automation and standardised processes can help, while lipid nanoparticle (LNP) formulation adds further technical demands. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has also consulted on how manufacturing and quality requirements should apply to individualised mRNA cancer therapies.

Moderna manages its manufacturing internally. The opportunity for specialist contract development and manufacturing organisations (CDMOs) will depend on whether other developers choose to outsource these processes, and at what cost.

Supply-Chain Risks Complicate mRNA Outsourcing

mRNA production relies on specialist enzymes, nucleotides, lipids and single-use components, some available from a limited pool of qualified suppliers. Shortages or delays can disrupt manufacturing schedules and increase costs.

US trade measures add uncertainty for CDMOs with international supply chains, although tariff exposure varies by product and origin. Smaller biotechnology companies can be particularly vulnerable to price increases and limited supplier choice.

Qualifying alternative suppliers takes time, while holding additional inventory ties up working capital. Sponsors assessing manufacturing partners need to understand where critical materials originate, how readily they can be replaced and who bears the cost when supply arrangements change.

Market Outlook: Growth Depends on Pipeline Progression

Visiongain forecasts the global mRNA contract manufacturing market will grow from US$4.62 billion in 2026 to US$13.52 billion by 2036, an 11.3% CAGR.

Demand is expected to broaden as mRNA programmes move beyond infectious disease vaccines into oncology and other therapeutic applications. Clinical progression could generate more work in formulation, analytical testing and commercial manufacturing, particularly among biotechnology companies reliant on external partners.

The pace of growth will depend on clinical success, outsourcing decisions and how effectively CDMOs convert development work into longer-term manufacturing contracts.

Visiongain Insight

The expanding mRNA pipeline offers opportunities for contract manufacturers, but clinical progress alone will not fill their facilities. Some programmes will fail, others may move in-house, and specialised production can be costly.

Winning development work is only the beginning. CDMOs must retain programmes as they advance, while managing the costs of small batches, complex formulations and demanding quality controls.

New facilities and expanded capabilities are worth watching, but they reveal little about future returns without evidence of customer demand. The stronger indicators are programmes progressing into commercial manufacturing, effective capacity utilisation and margins where disclosed. The challenge is keeping specialist facilities productive without allowing manufacturing complexity to erode profitability.

From Visiongain: Contract Manufacturing & CDMOs Hub

Visiongain’s Contract Manufacturing & CDMOs Hub brings together market forecasts and competitive intelligence covering pharmaceutical outsourcing, biologics and advanced therapies.

Related research:

• mRNA Contract Manufacturing Market Report 2026-2036
• Peptide Contract Manufacturing Market Report 2026-2036
• Pharmaceutical Contract Manufacturing Market Report 2026–2036
• Protein Contract Manufacturing Market Report 2026-2036
• Antibody Drug Conjugates Contract Manufacturing Market Report 2026-2036
• Vaccine Contract Manufacturing Market Report 2026-2036

Researching several manufacturing markets? Visiongain offers multi-report packages and tailored research to support market assessment, competitor benchmarking and investment decisions. Get in touch to discuss your research requirements.

Subscribe & Stay Ahead

📩 Subscribe to Visiongain Market Watch: Pharma, Biotech and Healthcare for weekly updates.

📚 Explore our comprehensive library at visiongain.com

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com